Revolutionizing vaccinology: The rise of mRNA vaccine

Ching Yu William Zhang

doi:10.54254/2753-8818/21/20230839

Research Article

Open access

Published on 20 December 2023

Download pdf

Zhang,C.Y.W. (2023). Revolutionizing vaccinology: The rise of mRNA vaccine. Theoretical and Natural Science,21,103-108.

Export citation

Revolutionizing vaccinology: The rise of mRNA vaccine

Ching Yu William Zhang *^,1,

¹ Shanghai Starriver Bilingual School

* Author to whom correspondence should be addressed.

https://doi.org/10.54254/2753-8818/21/20230839

Abstract

The public health sector has been greatly affected by the COVID-19 pandemic, and vaccines have become a crucial means of managing the virus. mRNA vaccines have gained prominence among the available vaccines due to their effectiveness and safety, marking a significant advancement in the field of biotechnology. Traditional vaccines have often resulted in severe symptoms and partial protection, while newer recombinant vaccines have significant drawbacks. In contrast, mRNA vaccines offer unprecedented cost-effectiveness, safety, and high efficacy per dose. The mRNA vaccines transport bioengineered mRNA to the human body, which translates into proteins that stimulate the immune response. However, there are some challenges associated with the development and production of mRNA vaccines, such as efficient delivery and maintaining the integrity of the mRNA molecule during storage and delivery. Despite these challenges, mRNA vaccines represent the future of vaccinology and the first line of defense against major infectious diseases. This paper explores the structure, mechanisms, immunology, and related areas of study concerning mRNA vaccines. The paper emphasizes the challenges in developing and producing mRNA vaccines and potential solutions to overcome these challenges.

Keywords

mRNA, vaccines, COVID-19 pandemic

View pdf

References

[1]. Riedel S. (2005). Edward Jenner and the history of smallpox and vaccination. Proceedings (Baylor University. Medical Center), 18(1), 21–25.

[2]. Jain, S., Venkataraman, A. K., Wechsler, M. E., & Peppas, N. A. (2021). Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic. Advanced Drug Delivery Reviews, 179, 114000–114000.

[3]. Pardi, N., Hogan, M., Porter, F. S., & Weissman, D. (2018). mRNA vaccines — a new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261–279.

[4]. Sandbrink, J. B., & Shattock, R. J. (2020). RNA Vaccines: A Suitable Platform for Tackling Emerging Pandemics? Frontiers in Immunology, 11.

[5]. Scorza, F. B., & Pardi, N. (2018). New Kids on the Block: RNA-Based Influenza Virus Vaccines. Vaccines, 6(2), 20.

[6]. Qu, L., Yi, Z., Shen, Y., Lin, L., Chen, F., Xu, Y., Wu, Z., Tang, H., Zhang, X., Tian, F., Wang, C., Xiao, X., Dong, X., Guo, L., Lu, S., Yang, C., Tang, C., Yang, Y., Yu, W., Wang, J., … Wei, W. (2022). Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell, 185(10), 1728–1744.e16.

[7]. Su, P., Zhang, L., Zhou, F., & Zhang, L. (2022). Circular RNA vaccine, a novel mRNA vaccine design strategy for SARS‐CoV‐2 and variants. MedComm, 3(3).

[8]. Huang, Y., Yang, C.-S., Xu, X., Xu, W., & Liu, S. (2020). Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacologica Sinica, 41(9), 1141–1149.

[9]. Verbeke, R., Lentacker, I., De Smedt, S., & Dewitte, H. (2021). The dawn of mRNA vaccines: The COVID-19 case. Journal of Controlled Release, 333, 511–520.

[10]. Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021). mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nature Reviews Drug Discovery, 20(11), 817–838.

Cite this article

Zhang,C.Y.W. (2023). Revolutionizing vaccinology: The rise of mRNA vaccine. Theoretical and Natural Science,21,103-108.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About volume

Volume title: Proceedings of the 3rd International Conference on Biological Engineering and Medical Science

Conference website: https://www.icbiomed.org/

ISBN：978-1-83558-215-2(Print) / 978-1-83558-216-9(Online)

Conference date: 2 September 2023

Editor：Alan Wang

Series: Theoretical and Natural Science

Volume number: Vol.21

ISSN：2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).